Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Prognostic factors in PRCC identified

Polifka I et al. Hum Pathol. 2018 Aug 16. doi: 10.1016/j.humpath.2018.08.006.

Publish date:: August 24, 2018

Key clinical point: Tumor proliferation, TNM stage, and patient age are independently prognostic in PRCC, whereas tumor subtype is not.

Major finding: Patients had poorer overall survival if they had high tumor MIB1 expression (hazard ratio, 2.465), higher tumor T stage (P = .036), or metastases (hazard ratio, 4.334), or were older (hazard ratio, 2.384).

Study details: A multicenter retrospective cohort study of 376 renal tumors initially diagnosed as PRCC.

Disclosures: The investigators disclosed that they had no relevant conflicts of interest. The study did not receive any specific funding.

Read the article.

Citation:

Polifka I et al. Hum Pathol. 2018 Aug 16. doi: 10.1016/j.humpath.2018.08.006.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Renal Cell Carcinoma

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Fear of recurrence highly prevalent in RCC survivors,

Risk factors for severe immune-related AEs identified,

Pembrolizumab plus axitinib continues to outshine sunitinib for advanced RCC,